EP0518983A4 - Tissu de gaze composite non pelucheux. - Google Patents

Tissu de gaze composite non pelucheux.

Info

Publication number
EP0518983A4
EP0518983A4 EP19910906141 EP91906141A EP0518983A4 EP 0518983 A4 EP0518983 A4 EP 0518983A4 EP 19910906141 EP19910906141 EP 19910906141 EP 91906141 A EP91906141 A EP 91906141A EP 0518983 A4 EP0518983 A4 EP 0518983A4
Authority
EP
European Patent Office
Prior art keywords
threads
coating
cellulose fiber
polymer
prepolymer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP19910906141
Other languages
German (de)
English (en)
Other versions
EP0518983A1 (fr
Inventor
Paul F Hermann
Henry B Sprague
Joel S Wildstein
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
United Foam Plastics Corp
Rynel Inc
Regenesis Inc
Original Assignee
United Foam Plastics Corp
Rynel Inc
Regenesis Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by United Foam Plastics Corp, Rynel Inc, Regenesis Inc filed Critical United Foam Plastics Corp
Publication of EP0518983A1 publication Critical patent/EP0518983A1/fr
Publication of EP0518983A4 publication Critical patent/EP0518983A4/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F13/00—Bandages or dressings; Absorbent pads
    • A61F13/00987—Apparatus or processes for manufacturing non-adhesive dressings or bandages
    • A61F13/00991—Apparatus or processes for manufacturing non-adhesive dressings or bandages for treating webs, e.g. for moisturising, coating, impregnating or applying powder
    • A61F13/00995—Apparatus or processes for manufacturing non-adhesive dressings or bandages for treating webs, e.g. for moisturising, coating, impregnating or applying powder for mechanical treatments
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F13/00—Bandages or dressings; Absorbent pads
    • A61F13/01—Non-adhesive bandages or dressings
    • A61F13/01008—Non-adhesive bandages or dressings characterised by the material
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F13/00—Bandages or dressings; Absorbent pads
    • A61F13/01—Non-adhesive bandages or dressings
    • A61F13/01034—Non-adhesive bandages or dressings characterised by a property
    • A61F13/01042—Absorbency
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L15/00—Chemical aspects of, or use of materials for, bandages, dressings or absorbent pads
    • A61L15/16—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons
    • A61L15/22—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons containing macromolecular materials
    • A61L15/26—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F13/00—Bandages or dressings; Absorbent pads
    • A61F2013/00089—Wound bandages
    • A61F2013/00238—Wound bandages characterised by way of knitting or weaving
    • A61F2013/00242—Wound bandages characterised by way of knitting or weaving to avoiding fraying or pilling
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F13/00—Bandages or dressings; Absorbent pads
    • A61F2013/00089—Wound bandages
    • A61F2013/00314—Wound bandages with surface treatments
    • A61F2013/00323—Wound bandages with surface treatments to make surface hydrophilic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F13/00—Bandages or dressings; Absorbent pads
    • A61F2013/00089—Wound bandages
    • A61F2013/00314—Wound bandages with surface treatments
    • A61F2013/00336—Wound bandages with surface treatments polymeric resins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F13/00—Bandages or dressings; Absorbent pads
    • A61F2013/00089—Wound bandages
    • A61F2013/00348—Wound bandages lint-free, i.e. non-linting or frying
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F13/00—Bandages or dressings; Absorbent pads
    • A61F2013/00361—Plasters
    • A61F2013/00727—Plasters means for wound humidity control
    • A61F2013/00731—Plasters means for wound humidity control with absorbing pads
    • A61F2013/0074—Plasters means for wound humidity control with absorbing pads containing foams

Definitions

  • This invention relates to substantially lint-free cotton gauze. Specifically it relates to a durable hydrophilic substantially non-linting water-absorbent drapable composite material comprising hydrophilic polymer resin applied to cellulosic fiber materials.
  • Cotton gauze is manufactured from twisted cotton fiber which is cleaned, bleached and sterilized. During the cleaning and bleaching process the thread is exposed to chemical treatments and becomes associated with leftover starch, proteins, casein, and resins. These materials, plus small fibers, can fall out of cotton gauze to contaminate a wound. During surgery, they may enter and remain undetected in the body to cause granulomas or they may enter the vascular system to cause even more serious conditions.
  • cellulose gauze While cellulose gauze is hydrophilic, the cellulose fibers are not normally broken down by human enzyme systems. The chronic presence of such cellulose fibers remaining in a patient post-operation causes an immune reaction in the patient resulting in inflamation and adhesion. The problem is apparently worsened by use of woven cotton swabs, over use of nonwoven cotton swabs. See Levinson & Swolin, "Postoperative Adhesions: Etiology, Prevention, and Therapy", Clin. Obst. & Gyn., 23(4); 1213-1220 (1980).
  • This invention involves wound dressing material which is substantially lint-free and highly water-absorbent.
  • the composite material of this invention comprises an open weave cellulose fiber material, such as cotton gauze, coated with a hydrophilic polymer. Although coated with a polymer, the composite material is highly water-absorbent, drapable, elastic and non-toxic, thus suitable for use in place of conventional gauze during surgical procedures.
  • the wound dressing material of the invention comprises an open weave cellulose fiber material having warp and fill threads. These threads are coated with a hydrophilic polymer film, leaving interstitial regions open among the threads.
  • the polymer is believed to specifically bind with the hydroxyl groups of the cellulose substantially to eliminate free particulate matter.
  • the cellulose fiber material may be woven cotton gauze, and is useful as a wound dressing or during surgery.
  • the polymer may be a polyurethane foam prepolymer applied to the gauze in aqueous solution.
  • the polymer may be a polyethylene oxide, or carboxymethyl cellulose, or a polyvinylpyrrolidone.
  • the preferred prepolymer is a toluene diisocyanate terminated polyethylene glycol, available as TREPOLTM from Twin Rivers Engineering, Boothbay, Maine.
  • the prepolymer aqueous solution may contain a surfactant, such as Pluronic® F68, available from BASF, to assure wetting.
  • Pluronic® F68 available from BASF
  • the polymer used to coat the cellulose fibers may be a blend of water to prepolymer in a ratio of from about 6:1 to about 400:1. This blend results in an increase in water absorbency, over untreated cotton gauze, usually in excess of 100 percent,' and often in excess of 200 percent.
  • the water absorbency of polymer-coated cellulose fibers of the invention can be in the range of from about 300 to 450 percent (weight of absorbed water in 3-4.5 times weight of dry gauze), compared with the water absorbency of untreated cellulose fiber which absorbs in the range of from about 200 to 250 percent.
  • the water to polymer ratio of the coating composition be sufficient effectively to bind particulate and resinous debris, without losing hydrophilicity, drapability or elasticity, and while maintaining an open weave structure.
  • skilled chemical engineers can manufacture the polymer-coated cellulose fiber material for use as wound dressing material.
  • Figure 1 illustrates the structure of an untreated section of woven cellulose fiber material showing warp and fill threads
  • Figure 2 is a schematic detailed view the intersection of an untreated warp thread and an untreated fill thread showing unbound particulate and resinous debris;
  • Figure 3 is a schematic detailed, partially broken away view of a thread coated in accordance with the invention.
  • Figure 4 illustrates an intersection of warp and fill threads, coated with the polymer in accordance with the invention.
  • Figure 5 is a schematic representation of a device for coating cellulose fiber material using the process of the invention.
  • FIG. 1 depicts typical woven cotton gauze 10, having warp threads 12 and fill threads 14 which are interwoven defining interstitial regions 16 between the warps 12 and fills 14. The presence of such interstitial regions makes this material an open weave, which enhances its absorbency.
  • Each thread of cotton gauze 10 is a twisting of multiple cotton fibers 11.
  • the chief constituent of cotton fiber 11 is cellulose. See Merrill, Macormac & Mauersberger, American Cotton Handbook. 88-89 (1949). The forces holding native cotton fiber together are hydrogen bonds between the hydroxyl groups in the cellulose.
  • the structure of cotton fiber 11 is that of many anhydroglucose units joined by an oxygen bridge between the 1:4 carbons to give long cellulose chains.
  • cotton fiber 11 also contains other materials such as proteins, waxes, and pectin. Thus, .there is some particulate matter associated with natural cotton fiber.
  • Cotton gauze 10, used primarily as a wound dressing is manufactured from twisted cotton fiber which is cleaned, bleached and sterilized. During the cleaning and bleaching process the thread is exposed to chemical treatments including combinations of acids, enzymes, alkalies, soda, sodium silicate, chlorine, sodium hydroxide, sulfuric acid, silicate of soda, turkey red oil or hydrogen peroxide.
  • Unbound particulate cotton fiber matter 20 and resinous debris 22, depicted in FIG. 2 may be left behind in wounds when cotton gauze is used as wound dressing material, causing adhesion and granulomas.
  • a polymer coating 25 may be used to cover the individual cotton warp threads and fill threads.
  • FIG's. 3 and 4 depict how the polymer coating 25 binds particulate cotton fiber material 20 and resinous debris 22 in accordance with the invention. Notice from FIG. 4 that the interstitial space 16 is maintained open and is not filled in with the polymer coating 25. This is important in maintaining a high degree of absorptivity.
  • the polymer coating produces polymer "fillets” 18 at the corner intersections of the warp 12 and fill 14 of the composite gauze material.
  • the fillets 18 consist of the polymer connection at the junction of warp and fill threads. They enable the material to better maintain and conserve the open weave structure during use. In untreated cotton gauze, there is resistance to deformation in the longitudinal direction, however the gauze is readily tearable in the lateral direction. The presence of the fillets 18 enhances the tensile strength of the material.
  • the composite material is made by applying a thin film of hydrophilic polymer to preformed woven cellulose fiber material of the type shown in FIGURE 1, i.e., conventional gauze.
  • Cellulose has several free hydroxyl groups which may react with a hydrophilic polymer forming covalent bonds.
  • the cellulose acts as a hydroxyl donor which can bond with an introduced polymer.
  • the polymer system used to form the coating typically is a thermosetting prepolymer mixture dissolved in an aqueous vehicle which, when cross-linked, is not water soluble.
  • the viscosity of the solution is important in achieving the thread-enveloping coating that maintains the open weave structure of the gauze. Viscosity and wettability of the coating solution is controlled in particular cases by adjusting the prepolymer/water ratio and blending with various surface active agents.
  • the treatment chemical is the prepolymer polyethylene oxide, available from Union Carbide.
  • This polymer forms a good association with compounds such as carboxy methyl cellulose, and also is reactive toward a hydroxyl donor, such as cellulose.
  • the polyethylene oxide may be mixed with the carboxy methyl cellulose at a ratio of 1:1.
  • polyethylene oxide and methyl cellulose are separately mixed at 6% by weight in water, then combined in a ratio of 1:1.
  • the resulting solution is applied to the gauze.
  • the solution cross-links, with irradiation, with the gauze and, in curing, forms an insoluble hydrophilic film on the individual threads thereof which retains free particulates.
  • This composite material may absorb as much as 1400 times its weight in water or more.
  • the treatment chemical is polyvinylpyrrolidone (see U.S. Patent No. 4,192,827).
  • the currently preferred polymer is a hydrophilic polyurethane foam prepolymer applied from aqueous solution and then reacted in situ.
  • the polyurethane foam may utilize any of a variety of urethane prepolymers normally employed for reaction to provide a reticulated, open cell foam.
  • a preferred class of hydrophilic urethane prepolymers includes, for example, isocyanate terminated or capped polyoxyalkylene ethers including polyoxyethylene polyol prepolymers. Suitable prepolymers are described in U.S. Patent No.
  • the preferred prepolymer is TREPOLTM polyurethane prepolymer available from Twin Rivers Engineering, Route #27, Boothbay, Maine, 04537.
  • the TREPOLTM prepolymer is a polyisocyanate terminated polyethylene polyol with less than 6% available unreacted NCO groups and a component functionality of 2 or less.
  • HYPOL 3000TM prepolymer may be used.
  • HYPOL 3000TM is a polyisocyanate capped polyoxyethylene polyol prepolymer having a reaction functionality of the prepolymer molecules greater than 2, and is available from W.R. Grace Company of New York.
  • exemplary surfactants include: Schercopol OMS-N, a disodium monooleamido MEA sulfosuccinate, available from the Scher Chemicals, Inc., Industrial West, Clifton, New Jersey 07012; PPG 1025, a polypropylene glycol surfactant; Pluronic® F68 or Pluronic® P75, nonionic surfactants which are block copolymers of propylene oxide and ethylene oxide, available from BASF; or, Alcolec HS-3, an active combination of lecithin and sulfonated glycerides in an aqueous solution, available from American Lecithin Company, 32-34 61st Street, Woodside, Long Island, New York 11377.
  • the hydrophilic prepolymer is activated by the aqueous phase for polymerization upon mixing.
  • the aqueous phase and the prepolymer are mixed together in a ratio by weight of aqueous phase to prepolymer sufficient to set an appropriate workable viscosity.
  • this ratio typically is in the range of from about 6:1 to about 400:1.
  • the solution constitutes a flowable, liquid incipient polyurethane which subsequently cures in situ after adhering to the threads.
  • the incipient foam is deposited on the open weave cellulose threads and excess water permeates the fiber.
  • hydrophilic urethane prepolymer in the ratio of from about 6:1 aqueous phase to prepolymer, to about 400:1 aqueous phase to prepolymer can produce a coated product that is highly water absorbent and meets the physical characteristics of durability, flexibility and drapablility.
  • the high water content of the mixture substantially eliminates foam formation when applied as a thin film to cotton gauze.
  • the result is a polymer coating which is water absorptive in combination with the cotton substructure, but does not have discrete, well defined cells.
  • the excess water in the polymerization reaction mixture permits adjustment of viscosity to allow the resulting solution to be applied readily to the threads of the cotton gauze. This rheological property of the solution permits automated production. Excess water also helps to dissipate exothermic heat and to limit the temperature of the reaction. Finally, the excess water assures that all available isocyanate sites are consumed or reacted, assuming nontoxicity of the resulting composition.
  • Co-pending U.S. Application Serial No. 013,255 teaches a method of manufacturing composite materials by use of a machine illustrated in FIG. 5.
  • the cotton gauze material with the incipient foamed resin of this invention can be manufactured using this type of equipment.
  • the aqueous resin coated gauze may be compressed to insure impregnation of the web with the resin and to establish the degree to which the polymer will occupy the interstitial regions of the fibers. Compression occurs at the adjustable nip of compression means 40, or between upper and lower parallel belts or conveyors of similar function (not shown) .
  • compression may occur between mold halves configured to impart shape to the surface of the composite material (not shown). In general, higher degrees of compression reduce the relative amount of incipient foam resin (lower foam density) and tend to promote greater preservation of voids among the fibers.
  • FIGURE 5 shows in schematic form the apparatus for performing the several steps of the method.
  • the woven cotton gauze fibrous material 30 is unrolled from supply rolls 32 and is advanced horizontally .
  • the individual sheets of material 30 pass through gathering means 33.
  • Blended liquid polyurethane foam resin or other hydrophilic resin is dispensed from a blender/dispenser means 34 and is deployed over the surface of the material 30.
  • the flowable, liquid incipient resin is allowed to penetrate the material 30 as the web advances.
  • the resin-coated material 36 is compressed by compression means 40 which may comprise, as is illustrated, an adjustable nip between a pair of compression rollers 41, 42.
  • the compression means 40 further distributes and makes uniform the resin within the material 36 and, by compression of the material, establishes the relative quantity, and therefore density distribution, of incipient resin carried within the material, thereby controlling the degree to which the foam will occupy the interstitial regions among the fibers of the material.
  • the resin-coated material is then taken through a curing means 50 where completion of the polymerization and curing of the urethane takes place.
  • the curing means 50 may include air heaters 52 or heated rollers (not shown) or both.
  • the curing means 50 may also comprise an exhaust fan system 54.
  • the polymer reaction and coating process may occur at room temperature.
  • the composite material 55 may pass over separation rollers 56, which assists in keeping multiple sheets of composite material 55 separated during the curing process.
  • the composite material 55 may pass through a pair of drive rollers 58, 59 and onto a take-up roll 60.
  • the drive rollers 58, 59 allow for multiple layers of composite material 55 to be combined into a single sheet for multi-layer gauze.
  • Cotton gauze may be treated as it is unrolled from its storage roll, or may be treated in • strips. Gauze also may be dipped in the polymer and massaged, rolled, or hung to dry. After extraction or evaporation of any liquid vehicles, which may be by room temperature or oven drying, the cured composite material may be cut to size or rolled as stock.
  • the effectiveness of the gauze treatment may be tested by putting test strips into boiling water and allowing the strip to be tossed around at a boil.
  • the resulting effluent then may be passed through a particle counter, such as a Coulter-counter.
  • a particle counter such as a Coulter-counter.
  • EG/HS-3 is a mixture of two surfactants: Emulgade 100NI, supplied by Henkel Corporation, which is a mixture of cetearyl alcohol and ceteaseth-20; and Alcolec HS-3, an active combination of lecithin and sulfonated glycerides in aqueous solution, supplied by American Lecithin Company. Emulgade and HS-3 were each made into 2.5% aqueous solutions, then mixed together to form a 95% water solution (or 5% EG/HS-3 aqueous solution).
  • F68 is Pluronic® F68, a nonionic surfactant of block copolymers of propylene oxide and ethylene oxide, supplied by BASF.
  • TREPOLTM is a toluene diisocyanate terminated polyethylene glycol with less than 6% available unreacted NCO groups and a component functionality of 2 or less. It is available from Twin Rivers Engineering, Route 27, Boothbay, Maine, 04537.
  • a surfactant such as F68
  • examples 2-3 illustrate that varying amounts of prepolymer, in combination with surfactant EG/HS-3, does not affect resin fallout.
  • examples 4-5 varying the amount of F68 surfactant alone does not affect resin fallout.
  • Examples 6-8 illustrate various ratios of water to prepolymer, whereby lower prepolymer concentration results in "closed gauze". Closed gauze is gauze with filled interstitial regions.
  • Examples 9-16 illustrate the effect of varying concentrations of prepolymer TREPOLTM to water on fiber and resin fallout. As demonstrated by these examples, an optimal ratio of 99.5 parts water, 0.5 parts surfactant F68, and 12 parts prepolymer TREPOLTM may result in a desired zero fiber fallout and zero resin fallout.
  • Example 11 differs from example 10 in that air was blown through the coated gauze in Example 11 to open the windows in the gauze. As demonstrated by this example 11, this additional step renders the gauze treatment suboptimal.
  • the invention may be embodied in other specific forms.

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Manufacturing & Machinery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Materials Engineering (AREA)
  • Epidemiology (AREA)
  • Materials For Medical Uses (AREA)
  • Treatments For Attaching Organic Compounds To Fibrous Goods (AREA)

Abstract

Tissu composite drapable non pelucheux, hydrophile et résistant, utilisable pour les pansements, composé de fibres de cellulose recouvertes de polymère hydrophile. Les fibres de cellulose peuvent être de la gaze de coton à armure ouverte (10). Le polymère hydrophile peut comporter un prépolymère de mousse de polyuréthane tel que le polyéthylène glycol à terminaison diisocyanate de toluène, contenant un agent de surface de façon optimale, ou bien comporter un oxyde de polyéthylène, une cellulose de carboxyméthyle ou une polyvinylpyrrolidone. Le rapport pondéral eau/prépolymère de la variante utilisant du polyuréthane est de préférence, de l'ordre d'environ 6:1 à environ 400:1. Le polymère hydrophile peut être un mélange de cellulose de carboxyméthyle et d'oxyde de polyéthylène.
EP19910906141 1990-03-06 1991-02-26 Tissu de gaze composite non pelucheux. Withdrawn EP0518983A4 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US48937990A 1990-03-06 1990-03-06
US489379 1990-03-06

Publications (2)

Publication Number Publication Date
EP0518983A1 EP0518983A1 (fr) 1992-12-23
EP0518983A4 true EP0518983A4 (fr) 1994-03-24

Family

ID=23943614

Family Applications (1)

Application Number Title Priority Date Filing Date
EP19910906141 Withdrawn EP0518983A4 (fr) 1990-03-06 1991-02-26 Tissu de gaze composite non pelucheux.

Country Status (6)

Country Link
EP (1) EP0518983A4 (fr)
CN (1) CN1054539A (fr)
AU (1) AU7468491A (fr)
CA (1) CA2077648A1 (fr)
WO (1) WO1991013602A1 (fr)
ZA (1) ZA911606B (fr)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9102089D0 (en) * 1991-01-31 1991-03-13 Johnson & Johnson Medical Net wound dressings
US6743965B2 (en) * 2000-12-21 2004-06-01 Mcneil-Ppc, Inc. Apertured polymeric film web with diol/surfactant additive
CN103749493B (zh) * 2014-02-14 2016-01-27 南京南农农药科技发展有限公司 一种含有井冈霉素a和噻呋酰胺的复配杀菌剂的悬浮剂及其制备方法
US10941252B2 (en) 2016-11-03 2021-03-09 3M Innovative Properties Company Silicone copolymers, methods of making, and articles
CN108355162B (zh) * 2018-05-14 2021-07-23 江西省科学院应用化学研究所 一种抗菌亲水性聚氨酯泡沫医用敷料
CN114288090B (zh) * 2021-12-30 2023-01-10 福建恒安卫生材料有限公司 一种具有氧气缓释功能的一次性卫生用品的制备方法
CN115120771A (zh) * 2022-06-30 2022-09-30 长沙海润生物技术有限公司 一种预收敛的激光烧结纱布敷料及其制备方法

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2764976A (en) * 1955-01-10 1956-10-02 Johnson & Johnson Dressing
US3317367A (en) * 1963-04-12 1967-05-02 Du Pont Hydrophobic fiber structure with interconnected non-fibrous hydrophilic network
GB2192142B (en) * 1986-07-04 1990-11-28 Johnson & Johnson Wound dressing

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
No further relevant documents disclosed *

Also Published As

Publication number Publication date
EP0518983A1 (fr) 1992-12-23
ZA911606B (en) 1991-12-24
AU7468491A (en) 1991-10-10
CN1054539A (zh) 1991-09-18
WO1991013602A1 (fr) 1991-09-19
CA2077648A1 (fr) 1991-09-07

Similar Documents

Publication Publication Date Title
US5135472A (en) Non-linting composite gauze material
CA2154473C (fr) Pansements pour plaies contenant du carboxymethylcellulose
JP5581328B2 (ja) 液体吸収材
CA1066466A (fr) Pansement chirurgical en mousse de polyurethane
US6534083B2 (en) Hydrogels
EP2773799B1 (fr) Structure tricotée pour pansements
US5676660A (en) Absorbent product including absorbent layer treated with surface active agent
CA2335563C (fr) Pansements et materiaux constitutifs adaptes
WO1994016746A1 (fr) Pansements pour blessures
US6458460B1 (en) Wound dressing
JPH0382893A (ja) 湿り架橋構造セルロース繊維の縦方向吸上構造
JPH08337674A (ja) 多糖フォームの製造方法
EP0518983A4 (fr) Tissu de gaze composite non pelucheux.
US6153214A (en) Wound dressing and manufacture thereof
CN117481910A (zh) 一种纳米银抗菌创可贴
WO2005067988A1 (fr) Pansement presentant une armure en oeil de perdrix
CZ76199A3 (cs) Obvaz na rány

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 19921001

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FR GB GR IT LI LU NL SE

17Q First examination report despatched

Effective date: 19950821

GRAG Despatch of communication of intention to grant

Free format text: ORIGINAL CODE: EPIDOS AGRA

GRAH Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOS IGRA

GRAH Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOS IGRA

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 19970902